Seroepidemiology and clinical aspects of human T-cell lymphotropic virus type I/II infection in a cohort of intravenous drug users in New York City.
To define further the magnitude, epidemiology, and clinical features of human T-cell lymphotropic/leukemia virus type I/II (HTLV-I/II) infection in 454 intravenous drug users in New York City, we evaluated previously frozen aliquots of sera for HTLV-I/II antibodies using enzyme-linked immunoassay, Western blot, and radioimmunoprecipitation techniques. We found HTLV-I/II infection in 18.9% of the subjects. Age (p = 0.001), race (p = 0.001), having a same gender sexual relationship (p = 0.01), and HIV-1 infection (p = 0.041) were clear correlates of HTLV-I/II infection. HTLV-I/II seropositive subjects, in contrast to seronegative subjects, had lower leukocyte counts (p = 0.05) and higher globulin (p = 0.005) and gamma globulin (p = 0.009) levels even when HIV-1 serostatus was controlled. The considerable prevalence of HTLV-I/II infection and the morbidity of HTLV-I/II-associated disorders strongly suggest a continued need to define the dimensions of HTLV-I/II infection.